Rainbow Coral Corp (RBCC) 0.0091 $RBCC
RBCC Aggressively Pursuing Personalized Medicine Opportunities in Canada
Business Wire - Tue May 05, 4:00AM CDT
Rainbow Coral Corp. (RBCC) is taking full advantage of more research-friendly regulations north of the border to target new personalized medicine opportunities in Canada. These opportunities include marketing cutting-edge treatments utilizing adult stem cells and the reprogramming of a patient's own existing cells to combat a variety of diseases, such as multiple sclerosis, ALS (Lou Gehrig's disease) and Parkinson's.
RBCC Targets Regenerative Medicine Leader to Build Out Partner Portfolio
Business Wire - Mon Apr 27, 4:00AM CDT
Following a series of productive meetings last week, biotech innovator Rainbow Coral Corp. (OTCBB: RBCC) targeted an emerging leader in the field of regenerative medicine for addition to its growing partner portfolio.
RBCC Weighs Opportunities Following Successful Events Schedule
Business Wire - Mon Mar 23, 4:00AM CDT
Following several successful conferences, events, and cross-country meetings, Rainbow Coral Corp. (OTCBB: RBCC) is sizing up potential investment and joint venture partners to expand its portfolio.
RBCC Joint Venture Partner n3D to Present Latest 3D Bioprinting Research in Washington, D.C.
Business Wire - Tue Feb 10, 4:00AM CST
Rainbow Coral Corp.'s (OTCBB:RBCC) 3D bioprinting joint venture partner Nano3D Biosciences (n3D) will present a new abstract detailing the latest breakthroughs made using its technology in Washington, D.C. on Wednesday at the 4th annual Society for Laboratory Automation and Screening Conference and Exhibition (SLAS2015).
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), AMGN: 163.44 (+1.08)
RBCC and n3D Pursue New Partnership Opportunities After Highly Successful 3D Bioprinting Exhibit at Biotech Showcase 2015
Business Wire - Thu Feb 05, 4:00AM CST
Rainbow Coral Corp. (OTCBB:RBCC) and Nano3D Biosciences (n3D) are lining up new 3D bioprinting opportunities and potential partnerships following a highly successful product exhibition last month at Biotech Showcase 2015 in San Francisco.
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), AMGN: 163.44 (+1.08)
3D Bioprinting Pioneers RBCC and n3D Biosciences Network With Top Biotechnology Investors This Week at Biotech Showcase 2015 in San Francisco
Business Wire - Tue Jan 13, 4:00AM CST
Rainbow Coral Corp. (OTCBB: RBCC) executive leadership will preview the latest innovations and network with top biotechnology investors this week at Biotech Showcase 2015 in San Francisco, where the company's joint venture partner, Nano3D Biosciences (n3D) will exhibit the revolutionary Bio-Assembler device.
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), AMGN: 163.44 (+1.08)
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), AMGN: 163.44 (+1.08)
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), VRX: 225.43 (+0.80), BMY: 68.00 (+0.36)
RBCC 3D Bioprinting Partner Awarded Prestigious Grant
Business Wire - Thu Jul 31, 5:54AM CDT
The joint venture of Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D), moved significantly closer to its funding goals this week thanks to a prestigious research grant from the National Institutes of Health.
ABT: 48.84 (+0.13), AMGN: 163.44 (+1.08)
RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses
Business Wire - Wed Jul 02, 4:00AM CDT
Work continues on a new injectable, sustained-release technology that Rainbow Coral Corp. (OTCBB: RBCC) hopes can help prevent a deadly epidemic of prescription narcotic overdoses.
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), VRX: 225.43 (+0.80), BMY: 68.00 (+0.36)
RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology
Business Wire - Thu Jun 26, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) works to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone, new research into the drug's potential could soon dramatically expand the drug's market and usage.
RBCC Aggressively Pursuing Personalized Medicine Opportunities in Canada
Business Wire - Tue May 05, 4:00AM CDT
Rainbow Coral Corp. (RBCC) is taking full advantage of more research-friendly regulations north of the border to target new personalized medicine opportunities in Canada. These opportunities include marketing cutting-edge treatments utilizing adult stem cells and the reprogramming of a patient's own existing cells to combat a variety of diseases, such as multiple sclerosis, ALS (Lou Gehrig's disease) and Parkinson's.
RBCC Targets Regenerative Medicine Leader to Build Out Partner Portfolio
Business Wire - Mon Apr 27, 4:00AM CDT
Following a series of productive meetings last week, biotech innovator Rainbow Coral Corp. (OTCBB: RBCC) targeted an emerging leader in the field of regenerative medicine for addition to its growing partner portfolio.
RBCC Weighs Opportunities Following Successful Events Schedule
Business Wire - Mon Mar 23, 4:00AM CDT
Following several successful conferences, events, and cross-country meetings, Rainbow Coral Corp. (OTCBB: RBCC) is sizing up potential investment and joint venture partners to expand its portfolio.
RBCC Joint Venture Partner n3D to Present Latest 3D Bioprinting Research in Washington, D.C.
Business Wire - Tue Feb 10, 4:00AM CST
Rainbow Coral Corp.'s (OTCBB:RBCC) 3D bioprinting joint venture partner Nano3D Biosciences (n3D) will present a new abstract detailing the latest breakthroughs made using its technology in Washington, D.C. on Wednesday at the 4th annual Society for Laboratory Automation and Screening Conference and Exhibition (SLAS2015).
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), AMGN: 163.44 (+1.08)
RBCC and n3D Pursue New Partnership Opportunities After Highly Successful 3D Bioprinting Exhibit at Biotech Showcase 2015
Business Wire - Thu Feb 05, 4:00AM CST
Rainbow Coral Corp. (OTCBB:RBCC) and Nano3D Biosciences (n3D) are lining up new 3D bioprinting opportunities and potential partnerships following a highly successful product exhibition last month at Biotech Showcase 2015 in San Francisco.
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), AMGN: 163.44 (+1.08)
3D Bioprinting Pioneers RBCC and n3D Biosciences Network With Top Biotechnology Investors This Week at Biotech Showcase 2015 in San Francisco
Business Wire - Tue Jan 13, 4:00AM CST
Rainbow Coral Corp. (OTCBB: RBCC) executive leadership will preview the latest innovations and network with top biotechnology investors this week at Biotech Showcase 2015 in San Francisco, where the company's joint venture partner, Nano3D Biosciences (n3D) will exhibit the revolutionary Bio-Assembler device.
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), AMGN: 163.44 (+1.08)
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), AMGN: 163.44 (+1.08)
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), VRX: 225.43 (+0.80), BMY: 68.00 (+0.36)
RBCC 3D Bioprinting Partner Awarded Prestigious Grant
Business Wire - Thu Jul 31, 5:54AM CDT
The joint venture of Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D), moved significantly closer to its funding goals this week thanks to a prestigious research grant from the National Institutes of Health.
ABT: 48.84 (+0.13), AMGN: 163.44 (+1.08)
RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses
Business Wire - Wed Jul 02, 4:00AM CDT
Work continues on a new injectable, sustained-release technology that Rainbow Coral Corp. (OTCBB: RBCC) hopes can help prevent a deadly epidemic of prescription narcotic overdoses.
ABT: 48.84 (+0.13), BIIB: 395.42 (+4.18), VRX: 225.43 (+0.80), BMY: 68.00 (+0.36)
RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology
Business Wire - Thu Jun 26, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) works to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone, new research into the drug's potential could soon dramatically expand the drug's market and usage.
